A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)

Model scores of the 29,894 trials active now.

Model score 2% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-09-18. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: purposeevidencepriorstudy iscompliance with
  Phrases that lowered it: healthythe pharmacokineticspharmacokinetics ofsinglemale subjects
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Primary purpose: other (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 10.5% (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 5.0% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 61.8% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 17 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: none (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 38 (lowers risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design
• Disease area, psychiatry: No (lowers risk) · Disease area
• Drug's FAERS reports before start: 92941 (lowers risk) · Drug's FDA history
• Maximum age: 45 (lowers risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 11152 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin NCT03339752 · started 2017 · scored riskier than 2% of active trials completed
• Clinical Study to Investigate the Effect of Macitentan on the Concentrations of Rosuvastatin in the Blood of Healthy Male Subjects NCT03359291 · started 2017 · scored riskier than 2% of active trials completed
• Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998) NCT05154123 · started 2021 · scored riskier than 1% of active trials completed
• Pharmacokinetics and Drug Interaction Study Between Rosuvastatin and CS-866 in Healthy Male Volunteers NCT01415466 · started 2011 · scored riskier than 0% of active trials completed
• A Study to Investigate How AZD4144 Affects the Pharmacokinetics of Rosuvastatin in Healthy Participants NCT06925854 · started 2025 · scored riskier than 1% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.